Figure 2From: Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5) Subject Accounting for MITT Analyses. There were no health care encounters on the first day of vaccination among 26 infants without follow-up after the first day of vaccination.Back to article page